R Benjamin Free - Publications

Affiliations: 
2003- National Institutes of Health, Bethesda, MD 

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Moritz AE, Bonifazi A, Guerrero AM, Kumar V, Free RB, Lane JR, Verma RK, Shi L, Newman AH, Sibley DR. Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. Acs Chemical Neuroscience. PMID 32969645 DOI: 10.1021/acschemneuro.0c00425  0.88
2020 Ågren R, Zeberg H, Maciej Stępniewski T, Free RB, Reilly SW, Luedtke RR, Århem P, Ciruela F, Sibley DR, Mach RH, Selent J, Nilsson J, Sahlholm K. A ligand with two modes of interaction with the dopamine D2 receptor - An induced-fit mechanism of insurmountable antagonism. Acs Chemical Neuroscience. PMID 32865974 DOI: 10.1021/Acschemneuro.0C00477  0.88
2020 Moritz AE, Free RB, Weiner WS, Akano EO, Gandhi D, Abramyan A, Keck TM, Ferrer M, Hu X, Southall N, Steiner J, Aubé J, Shi L, Frankowski KJ, Sibley DR. Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist. Journal of Medicinal Chemistry. PMID 32342685 DOI: 10.1021/Acs.Jmedchem.0C00424  0.88
2020 Sanchez-Soto M, Verma RK, Willette BKA, Gonye EC, Moore AM, Moritz AE, Boateng CA, Yano H, Free RB, Shi L, Sibley DR. A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. Science Signaling. 13. PMID 32019899 DOI: 10.1126/Scisignal.Aaw5885  0.88
2020 Prabhu VV, Morrow S, Cuoco CA, Kawakibi AR, Jung J, Madhukar N, Garnett MJ, McDermott U, Benes CH, Wechsler-Reya R, Anantharaman L, Charter N, Rucker JB, Doranz BJ, Basken J, ... ... Free RB, et al. Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology Cancer Research. 80: 5688-5688. DOI: 10.1158/1538-7445.Am2020-5688  0.88
2019 Keck TM, Free RB, Day MM, Brown SL, Maddaluna MS, Fountain G, Cooper C, Fallon B, Holmes M, Stang C, Burkhardt R, Bonifazi A, Ellenberger MP, Newman AH, Sibley DR, et al. Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry. PMID 30883109 DOI: 10.1021/Acs.Jmedchem.9B00231  0.88
2019 Farino ZJ, Morgenstern TJ, Maffei A, Quick M, De Solis AJ, Wiriyasermkul P, Freyberg RJ, Aslanoglou D, Sorisio D, Inbar BP, Free RB, Donthamsetti P, Mosharov EV, Kellendonk C, Schwartz GJ, et al. New roles for dopamine D and D receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry. PMID 30626912 DOI: 10.1038/S41380-018-0344-6  0.88
2019 Prabhu VV, Kawakibi AR, Madhukar N, Garnett MJ, McDermott U, Benes CH, Anantharaman L, Charter N, Deacon S, VanEngelenburg A, Rucker JB, Doranz BJ, Rusert J, Wechsler-Reya R, Elemento O, ... ... Free RB, et al. Abstract 3877: IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology Cancer Research. 79: 3877-3877. DOI: 10.1158/1538-7445.Sabcs18-3877  0.88
2018 Chun LS, Vekariya RH, Free RB, Li Y, Lin DT, Su P, Liu F, Namkung Y, Laporte SA, Moritz AE, Aubé J, Frankowski KJ, Sibley DR. Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the DDopamine Receptor. Frontiers in Synaptic Neuroscience. 10: 2. PMID 29515433 DOI: 10.3389/Fnsyn.2018.00002  0.88
2018 Verma RK, Abramyan AM, Michino M, Free RB, Sibley DR, Javitch JA, Lane JR, Shi L. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. Plos Computational Biology. 14: e1005948. PMID 29337986 DOI: 10.1371/Journal.Pcbi.1005948  0.88
2018 Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry WS, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Deacon S, Charter N, Free RB, Oster W, et al. Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 Cancer Research. 78: 3857-3857. DOI: 10.1158/1538-7445.Am2018-3857  0.44
2018 Madhukar NS, Prabhu VV, Anantharaman L, Sulli C, Davidson E, Deacon S, Rucker J, Charter N, Doranz B, Oster W, Elemento O, Free RB, Sibley D, Allen JE. Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B130  0.44
2018 Cuoco CA, Free RB, Willette BK, Day MM, Lane JR, Allen JE, Sibley DR. Characterization of the novel anti-cancer therapeutic ONC201 and related analogs as non-competitive antagonists of the D2 dopamine receptor The Faseb Journal. 32. DOI: 10.1096/Fasebj.2018.32.1_Supplement.827.10  0.88
2017 Moritz AE, Benjamin Free R, Sibley DR. Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cellular Signalling. PMID 28716664 DOI: 10.1016/J.Cellsig.2017.07.003  0.8
2017 Kumar V, Moritz AE, Keck TM, Bonifazi A, Ellenberger MP, Sibley CD, Free RB, Shi L, Lane JR, Sibley DR, Newman AH. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). Journal of Medicinal Chemistry. PMID 28186762 DOI: 10.1021/Acs.Jmedchem.6B01688  0.88
2016 Zou MF, Keck TM, Kumar V, Donthamsetti P, Michino M, Burzynski C, Schweppe C, Bonifazi A, Free RB, Sibley DR, Janowsky A, Shi L, Javitch JA, Newman AH. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. Journal of Medicinal Chemistry. PMID 27035329 DOI: 10.1021/Acs.Jmedchem.5B01612  0.88
2016 Luderman KD, Conroy JL, Free RB, Southall NT, Ferrer M, Aubé J, Frankowski KJ, Sibley DR. Structurally Diverse Positive Allosteric Modulators of the D1 Dopamine Receptor Potentiate G‐Protein and β‐Arrestin‐Mediated Signaling The Faseb Journal. 30. DOI: 10.1096/Fasebj.30.1_Supplement.931.9  0.88
2015 Michino M, Free RB, Doyle TB, Sibley DR, Shi L. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. Chemical Communications (Cambridge, England). 51: 8618-21. PMID 25896577 DOI: 10.1039/C5Cc02204E  0.88
2015 Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. Acs Chemical Neuroscience. 6: 681-92. PMID 25660762 DOI: 10.1021/Acschemneuro.5B00020  0.88
2015 Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8  0.88
2015 Chun LS, Benjamin Free R, Sibley DR. Calcium and phospholipase Cβ signaling through dopamine receptors Neuromethods. 96: 251-263. DOI: 10.1007/978-1-4939-2196-6_14  0.72
2014 Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 25583363 DOI: 10.1016/J.Euroneuro.2014.11.013  0.88
2014 Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant-Genevier M, et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Molecular Pharmacology. 86: 96-105. PMID 24755247 DOI: 10.1124/Mol.113.090563  0.88
2014 Xiao J, Free RB, Barnaeva E, Conroy JL, Doyle T, Miller B, Bryant-Genevier M, Taylor MK, Hu X, Dulcey AE, Southall N, Ferrer M, Titus S, Zheng W, Sibley DR, et al. Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists. Journal of Medicinal Chemistry. 57: 3450-63. PMID 24666157 DOI: 10.1021/Jm500126S  0.88
2013 Chun LS, Free RB, Doyle TB, Huang XP, Rankin ML, Sibley DR. D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms. Molecular Pharmacology. 84: 190-200. PMID 23680635 DOI: 10.1124/Mol.113.085175  0.88
2013 Free RB, Conroy JL, Roof RA, Doyle T, Han Y, Donthamsetti P, Javitch JA, Southall N, Emmitte K, Lindsley C, Ferrer M, Sibley DR. High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 115. DOI: 10.1016/B978-0-12-800044-1.00101-X  0.88
2013 Conroy JL, Free RB, Doyle TB, Sibley DR. Identification of Substituted Benzazepines as Functionally Selective Ligands of the D1 Dopamine Receptor Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 113. DOI: 10.1016/B978-0-12-800044-1.00099-4  0.88
2013 Chun LS, Free RB, Doyle TB, Huang XP, Sibley DR. Investigation of the D1-D2 heteromer: Pharmacology, subunit composition, and mechanisms of signaling Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 106. DOI: 10.1016/B978-0-12-800044-1.00092-1  0.88
2013 Sibley DR, Free RB, Namkung Y, Lisa A. Sorting NEXIN-25 Interacts with D1 and D2Dopamine Receptors to Regulate Receptor Expression and Signaling Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 96-97. DOI: 10.1016/B978-0-12-800044-1.00083-0  0.88
2010 Rankin ML, Hazelwood LA, Free RB, Namkung Y, Rex EB, Roof RA, Sibley DR. Molecular Pharmacology of the Dopamine Receptors Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0006  0.88
2009 Free RB, Hazelwood LA, Sibley DR. Identifying novel protein-protein interactions using co-immunoprecipitation and mass spectroscopy. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 5.28. PMID 19170023 DOI: 10.1002/0471142301.Ns0528S46  0.88
2008 Hazelwood LA, Free RB, Cabrera DM, Skinbjerg M, Sibley DR. Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+,K+-ATPase. The Journal of Biological Chemistry. 283: 36441-53. PMID 18984584 DOI: 10.1074/Jbc.M805520200  0.88
2007 Free RB, Hazelwood LA, Cabrera DM, Spalding HN, Namkung Y, Rankin ML, Sibley DR. D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. The Journal of Biological Chemistry. 282: 21285-300. PMID 17395585 DOI: 10.1074/Jbc.M701555200  0.88
2006 D'Souza VM, Foraker AB, Free RB, Ray A, Shapiro PS, Swaan PW. cAMP-Coupled riboflavin trafficking in placental trophoblasts: a dynamic and ordered process. Biochemistry. 45: 6095-104. PMID 16681382 DOI: 10.1021/Bi060138F  0.88
2006 Free RB, Kaser DJ, Boyd RT, McKay DB. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors. Neuroscience Letters. 392: 135-9. PMID 16198480 DOI: 10.1016/J.Neulet.2005.09.002  0.88
2003 Free RB, von Fischer ND, Boyd RT, McKay DB. Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells. Neuroscience Letters. 343: 180-4. PMID 12770692 DOI: 10.1016/S0304-3940(03)00381-1  0.88
2003 Free RB, McKay DB. Surface and intracellular nicotinic receptors expressed in intact adrenal chromaffin cells: direct measurements using [3H]epibatidine. Brain Research. 974: 60-9. PMID 12742624 DOI: 10.1016/S0006-8993(03)02551-4  0.88
2002 McKay DB, Free RB, Kaser DJ, McKay SB. Characterization of [(3)H]epibatidine binding to nicotinic receptors from bovine adrenal medulla. Annals of the New York Academy of Sciences. 971: 162-4. PMID 12438112 DOI: 10.1111/J.1749-6632.2002.Tb04456.X  0.88
2002 Free RB, McKay SB, Boyd RT, McKay DB. Evidence for constitutive expression of bovine adrenal a3beta4* nicotinic acetylcholine receptors. Annals of the New York Academy of Sciences. 971: 145-7. PMID 12438106 DOI: 10.1111/J.1749-6632.2002.Tb04450.X  0.88
2002 Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, Arason KM, Bergmeier SC, McKay DB. Effects of methyllycaconitine and related analogues on bovine adrenal alpha3beta4* nicotinic acetylcholine receptors. Annals of the New York Academy of Sciences. 971: 139-41. PMID 12438104 DOI: 10.1111/J.1749-6632.2002.Tb04448.X  0.88
2002 Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, McKay SB, Bergmeier SC, McKay DB. Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal alpha3beta4* nicotinic receptors. Neuroscience Research. 42: 57-63. PMID 11814609 DOI: 10.1016/S0168-0102(01)00304-2  0.88
2002 Free RB, Bryant DL, McKay SB, Kaser DJ, McKay DB. [3H]Epibatidine binding to bovine adrenal medulla: evidence for alpha3beta4* nicotinic receptors. Neuroscience Letters. 318: 98-102. PMID 11796195 DOI: 10.1016/S0304-3940(01)02489-2  0.88
2001 Free RB, McKay DB. Receptor protection studies to characterize neuronal nicotinic receptors: tubocurarine prevents alkylation of adrenal nicotinic receptors. Brain Research. 891: 176-84. PMID 11164821 DOI: 10.1016/S0006-8993(00)03204-2  0.88
2000 Free RB, Wenger BW, McKay DB. Effects of sulfhydryl modification on adrenal nicotinic acetylcholine receptors: disulfide integrity is not essential for activation. Life Sciences. 68: 373-85. PMID 11205888 DOI: 10.1016/S0024-3205(00)00943-7  0.88
1999 Bergmeier SC, Lapinsky DJ, Free RB, McKay DB. Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists. Bioorganic & Medicinal Chemistry Letters. 9: 2263-6. PMID 10465558 DOI: 10.1016/S0960-894X(99)00378-9  0.88
Show low-probability matches.